Novel antiplatelet and anticoagulant agents in the cardiac care unit

This article reviews the pivotal studies of several novel antiplatelet (prasugrel and ticagrelor) and anticoagulant (dabigatran, rivaroxaban, and apixaban) agents. The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic...

Full description

Saved in:
Bibliographic Details
Published inCardiology clinics Vol. 31; no. 4; p. 533
Main Authors Garg, Vaani Panse, Halperin, Jonathan L
Format Journal Article
LanguageEnglish
Published Netherlands 01.11.2013
Subjects
Acute Coronary Syndrome - drug therapy
Acute Disease
Administration, Oral
Anticoagulants - therapeutic use
Atrial Fibrillation - prevention & control
Coronary Care Units
Critical Care
Drug Therapy, Combination
Electric Countershock - methods
Heart Valve Prosthesis
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
Intraoperative Care - methods
Platelet Aggregation Inhibitors - therapeutic use
Pulmonary Embolism - prevention & control
Time Factors
Venous Thromboembolism - prevention & control
Venous Thrombosis - prevention & control
Anticoagulants
Stroke
Atrial fibrillation
Antiplatelet drugs
Percutaneous coronary intervention
Acute coronary syndrome
Venous thromboembolism
Online AccessGet more information

Cover

More Information
Summary:This article reviews the pivotal studies of several novel antiplatelet (prasugrel and ticagrelor) and anticoagulant (dabigatran, rivaroxaban, and apixaban) agents. The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic stroke, atrial fibrillation, and venous thromboembolism.
ISSN:1558-2264
DOI:10.1016/j.ccl.2013.07.001